02/21
Headlines

BioTech

Biotech Stocks Touching New Highs: BioSpecifics Technologies (NASDAQ:BSTC), NanoString Technologies (NASDAQ:NSTG), Celladon (NASDAQ:CLDN), Receptos (NASDAQ:RCPT)

Adam Keintzel02 mins

BioSpecifics Technologies Corp. (NASDAQ:BSTC) released its earnings data on Thursday. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.17 by $0.08, Stock Ratings Network.com reports. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 1.56% in last session and finished the day at $26.72. Traded volume was 32,149.00 shares in…

Read More

Biotech Losers: CytRx Corporation (NASDAQ:CYTR), Galena Biopharma (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Chris Lewis02 mins

CytRx Corporation (NASDAQ:CYTR) reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) stock performance was -12.76% in last session and finished the day at $4.17. Traded volume was 11,065,087 million shares in the last…

Read More

Biotech Gainers: Geron Corporation (NASDAQ:GERN), Chelsea Therapeutics International (NASDAQ:CHTP), TESARO Inc (NASDAQ:TSRO), Vanda Pharmaceuticals (NASDAQ:VNDA)

Mark DeFrance02 mins

Geron Corp. (NASDAQ:GERN)‘s stock had its “positive” rating reaffirmed by equities researchers at Wells Fargo & Co. in a research report issued on Thursday, AnalystRatings.NETreports. Geron Corporation (NASDAQ:GERN) stock performance was 5.62% in last session and finished the day at $1.78. Traded volume was 16,397,352 million shares in the last session and the average volume…

Read More

Biotech Unusual Volume: OXiGENE Inc (NASDAQ:OXGN), TESARO Inc (NASDAQ:TSRO), Discovery Laboratories (NASDAQ:DSCO), Albany Molecular Research (NASDAQ:AMRI)

Jason Knox02 mins

OXiGENE Inc (NASDAQ:OXGN) on Mar. 11 announced positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less…

Read More

Biotech Most Active Stocks: Geron Corporation (NASDAQ:GERN), Pfizer Inc. (NYSE:PFE), OXiGENE Inc (NASDAQ:OXGN), Gilead Sciences (NASDAQ:GILD)

Kevin Long02 mins

Geron Corporation (NASDAQ:GERN)  got bad news about its key imetelstat drug, as the FDA issued a clinical hold on the treatment for multiple myeloma and essential thrombocythemia. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the…

Read More

Biotech Unusual Volume Stocks: Arca Biopharma (NASDAQ:ABIO), Biota Pharmaceuticals (NASDAQ:BOTA), Lpath (NASDAQ:LPTN), La Jolla Pharmaceutical (NASDAQ:LJPC)

Mark DeFrance02 mins

Arca Biopharma Inc (NASDAQ:ABIO) focuses on developing genetically targeted therapies for cardiovascular disease. Its lead product candidate, Gencaro, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. Arca Biopharma Inc (NASDAQ:ABIO) stock performance was 11.34% in…

Read More